| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 4159- | dietSTF, | 2DG, | CRMs, | Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms |
| - | Review, | AD, | NA |
| 3708- | dietSTF, | Fasting as a Therapy in Neurological Disease |
| - | Review, | Nor, | NA |
| 1626- | dietSTF, | dietFMD, | When less may be more: calorie restriction and response to cancer therapy |
| - | Review, | Var, | NA |
| - | Trial, | Cerv, | NA |
| 8834- | DIM, | Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial |
| - | Trial, | Cerv, | NA |
| 8827- | DIM, | Inhibition of breast cancer cell growth and induction of cell death by 1,1-bis(3'-indolyl)methane (DIM) and 5,5'-dibromoDIM |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 8832- | DIM, | Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy |
| - | Trial, | Pca, | NA |
| 8843- | DIM, | 3,3′-diindolylmethane induces ferroptosis and inhibits proliferation in non-small-cell lung cancer through the AHR/NRF2/GPX4 axis |
| - | in-vitro, | NSCLC, | NA |
| 8850- | DIM, | 3,3'-Diindolylmethane Enhances Tumor Regression After Radiation Through Protecting Normal Cells to Modulate Antitumor Immunity |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 8847- | DIM, | Studies on the mode of action of synthetic diindolylmethane derivatives against triple negative breast cancer cells |
| - | in-vitro, | BC, | NA |
| 8846- | DIM, | ORM, | Diindolylmethane Promotes Metabolic Crisis and Enhances the Efficacy of Centchroman in Breast Cancer: A 1H NMR-Based Approach |
| - | vitro+vivo, | BC, | NA |
| 6734- | Dipy, | Cisplatin, | Adenosine enhances cisplatin sensitivity in human ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 6277- | DL, | docx, | d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | PZ-HPV-7 |
| 6281- | DL, | Applications of Limonene in Neoplasms and Non-Neoplastic Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Diabetic, | NA |
| 5386- | docx, | AsP, | Co-delivery of docetaxel and palmitoyl ascorbate by liposome for enhanced synergistic antitumor efficacy |
| - | vitro+vivo, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Pca, | PC3 |
| 6342- | DRE, | Mechanistic Study on the Inhibitory Effect of Dandelion Extract on Breast Cancer Cell Proliferation and Its Induction of Apoptosis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 6348- | DRE, | New prospects in oncotherapy: bioactive compounds from Taraxacum officinale |
| - | Review, | Var, | NA |
| 6317- | DRE, | The efficacy of dandelion root extract in inducing apoptosis in drug-resistant human melanoma cells |
| - | in-vitro, | Melanoma, | A375 |
| 6320- | DRE, | Selective induction of apoptosis and autophagy through treatment with dandelion root extract in human pancreatic cancer cells |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 |
| 6322- | DRE, | LGE, | Dandelion Root and Lemongrass Extracts Induce Apoptosis, Enhance Chemotherapeutic Efficacy, and Reduce Tumour Xenograft Growth In Vivo in Prostate Cancer |
| - | vitro+vivo, | Pca, | DU145 |
| 6354- | DRE, | Taraxacum officinale L. in leukemia and lymphoma: current knowledge and prospects for horticulture |
| - | Review, | AML, | NA |
| 6351- | DRE, | Rad, | Differential effect of Taraxacum officinale L. (dandelion) root extract on hepatic and testicular tissues of rats exposed to ionizing radiation |
| - | in-vivo, | Nor, | NA |
| 6738- | DSF, | Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4 |
| - | Review, | Var, | NA |
| 6744- | DSF, | Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D |
| 6739- | DSF, | Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 |
| 4913- | DSF, | Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies |
| - | Review, | Var, | NA |
| 4914- | DSF, | immuno, | Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies |
| - | Review, | Var, | NA |
| 5008- | DSF, | Cu, | Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis |
| - | in-vitro, | HCC, | NA |
| - | vitro+vivo, | lymphoma, | NA |
| 5011- | DSF, | Cu, | Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens |
| - | Review, | Var, | NA |
| 5012- | DSF, | Cu, | Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems |
| - | Review, | Var, | NA |
| 5006- | DSF, | Cu, | Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition |
| - | vitro+vivo, | lymphoma, | NA |
| 4832- | EA, | Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid |
| - | Review, | Var, | NA |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1619- | EA, | CUR, | effect-of-the-ellagic-acid-and-curcumin-combinations-2161-0525-1000296.pdf">Antimutagenic Effect of the Ellagic Acid and Curcumin Combinations |
| - | in-vitro, | Nor, | NA |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 1611- | EA, | Targeting Myeloperoxidase Activity and Neutrophil ROS Production to Modulate Redox Process: Effect of Ellagic Acid and Analogues |
| - | in-vitro, | Mal, | NA |
| 1618- | EA, | A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action |
| - | Review, | BC, | NA |
| 6612- | Ech, | Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial |
| - | Trial, | Nor, | NA |
| 6606- | Ech, | Cic, | Cytotoxic effects of Echinacea purpurea flower extracts and cichoric acid on human colon cancer cells through induction of apoptosis |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Colon, | HCT116 |
| 6607- | Ech, | Cytotoxic effects of Echinacea root hexanic extracts on human cancer cell lines |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | CRC, | Colo320 |
| 6619- | Ech, | Echinacea Reduces Antibiotics by Preventing Respiratory Infections: A Meta-Analysis (ERA-PRIMA) |
| - | Review, | Nor, | NA |
| 7200- | EGb 761, | PCA, | Optimized Ginkgo biloba extract EGb 761®: boosted therapeutic benefits with minimized CYP enzyme interference |
| - | in-vivo, | Nor, | NA |
| 7231- | EGb 761, | Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials |
| - | Review, | AD, | NA |
| 7222- | EGb 761, | Ginkgo biloba extract EGb 761® in the symptomatic treatment of mild-to-moderate dementia: a profile of its use |
| - | Review, | AD, | NA |
| 7239- | EGb 761, | Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis |
| - | Review, | AD, | NA |
| 7220- | EGb 761, | Ginkgo Biloba Extract Inhibits Metastasis and ERK/Nuclear Factor kappa B (NF-κB) Signaling Pathway in Gastric Cancer |
| - | vitro+vivo, | GC, | SGC-7901 |
| 3220- | EGCG, | Dual Roles of Nrf2 in Cancer |
| - | in-vitro, | Lung, | A549 |
| 3202- | EGCG, | Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | HCC, | QGY-7703 |
| 6787- | EGCG, | statins, | An Update on Impacts of Epigallocatechin Gallate Co-administration in Modulating Pharmacokinetics of Statins, Calcium Channel Blockers, and Beta-blockers |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid